分子靶向药特罗凯对晚期肺癌的抗肿瘤活性分析  

Anti-tumor Effect of Molecular Targeted Drug Tarceva on Advanced Lung Cancer

作　　者：邬红霞 矫艳艳 冒小燕[2] 

机构地区：[1]山东省青岛市城阳区人民医院,266109 [2]上海交通大学附属第六人民医院,200233

出　　处：《实用癌症杂志》2015年第8期1170-1173,共4页The Practical Journal of Cancer

摘　　要：目的探讨分子靶向药特罗凯对晚期肺癌的抗肿瘤活性。方法收集晚期肺癌患者50例,口服特罗凯150 mg,每天1次,随访1年,观察分子靶向药特罗凯对晚期肺癌的抗肿瘤的疗效及不良反应。结果分子靶向药特罗凯对晚期肺癌的抗肿瘤治疗有效率男性高于女性、低年龄段高于高年龄段,差异均具有统计学意义(P均<0.05);对中央型肺癌和周围型肺癌治疗有效率之间差异无统计学意义(P>0.05)。治疗控制率在不同性别、不同病变位置之间差异无统计学意义(P>0.05),在不同年龄段控制率之间差异具有统计学意义(P<0.05)。患者总的中位生存时间为9.714个月,95%CI为9.557~10.443个月。经过分析男性中位生存时间高于女性,低年龄患者中位生存时间高于高年龄患者,病变中央型患者中位生存时间高于周围型患者,但差异均无统计学意义(P>0.05)。不良反应在男女之间、病变位置之间差异无统计学意义(P>0.05)。结论分子靶向药特罗凯对于晚期肺癌具有一定疗效,尤其是对男性和低年龄段群体,同时不良反应可以有效控制,安全性较高。Objective To investigate the anti-tumor effect of molecular targeted drug Tarceva on advanced lung cancer.Methods 50 cases of lung cancer patients received oral Tarceva 150 mg,once a day,followed up 1 year,anti-tumor efficacy and adverse reactions of molecular targeted drug Tarceva for advanced lung cancer were observed. Results Anti-tumor efficacy of molecular targeted drug Tarceva for male advanced lung cancer patients was better than those of female patients,younger patients was better than those of elderly patients,there had statistically significant difference( P < 0. 05),there had no significant difference in the treatment efficiency between central lung cancer and peripheral lung cancer( P > 0. 05); treatment control rates of different gender,and different lesion locations had no significant difference( P > 0. 05),but there had statistically significant difference in the treatment control rate of patients at different ages( P < 0. 05); Overall median survival time was 9. 714 months,95% CI was9. 557 ~ 10. 443 months. Analysis showed that median survival time of male patients was higher than those of female patients,younger patients was higher than those of elderly patients,patients with central lesion was higher than patients with peripheral lesion,but there had no statistically significant difference( P > 0. 05); There had no significant difference in the adverse reactions between male and female patients,and patients with different lesion locations( P > 0. 05). Conclusion Molecular targeted drug Tarceva for advanced lung cancer is effective and safe,especially in male patients and younger patients,the adverse reactions is tolerable.

关 键 词：分子靶向 特罗凯 晚期肺癌 抗肿瘤活性 

分 类 号：R734.2[医药卫生—肿瘤]